PHATHOM PHARMACEUTICALS, INC.
PHAT · NASDAQ
Phathom Pharmaceuticals is a biopharmaceutical company focused on the development and commercialization of novel treatments for gastrointestinal diseases and disorders. Phathom has in-licensed the exclusive rights in the United States, Europe, and Canada to vonoprazan, a novel potassium competitive acid blocker (P-CAB) in late-stage development for the treatment of acid-related disorders.
ESG Scores
Overall ESG7.0
Environmental5.6
Social5.0
Governance5.2
Gender Diversity
Female Directors0.25%
Female Executives0.6341463414634146%
CEO GenderFemale
Market Data
Price$9.86-0.23 (-2.28%)
Market Cap$805M
P/E Ratio—
EPS$—
52W High$18.31
52W Low$4.47
Beta0.47